Search Results
You are looking at 1 - 3 of 3 items for
- Author: Manila Rubino x
- Refine by access: All content x
Laboratory of Geriatric and Oncologic Neuroendocrinology Research, Istituto Auxologico Italiano IRCCS, Milan, Italy
Search for other papers by Giovanni Vitale in
Google Scholar
PubMed
Search for other papers by Alessandra Dicitore in
Google Scholar
PubMed
Search for other papers by Concetta Sciammarella in
Google Scholar
PubMed
Search for other papers by Sergio Di Molfetta in
Google Scholar
PubMed
Search for other papers by Manila Rubino in
Google Scholar
PubMed
Search for other papers by Antongiulio Faggiano in
Google Scholar
PubMed
Search for other papers by Annamaria Colao in
Google Scholar
PubMed
Somatostatin analogs have an important role in the medical therapy of neuroendocrine tumors (NETs). Octreotide and lanreotide, both somatostatin analogs binding with high affinity for the somatostatin receptor (SSTR)2, can control symptoms in functional NETs. In addition, these compounds, because of their antiproliferative effects, can stabilize growth of well-differentiated NETs. Pasireotide is a novel multireceptor-targeted somatostatin analog with high affinity for SSTR1, 2, 3, and 5. This review provides an overview of the state of the art of pasireotide in the treatment of NETs, with the aim of addressing clinical relevance and future perspectives for this molecule in the management of NETs.
Department of Oncology and Hemato-Oncology (DIPO), University of Milan, Milan, Italy
Search for other papers by Carmine Valenza in
Google Scholar
PubMed
Search for other papers by Francesca Spada in
Google Scholar
PubMed
Search for other papers by Francesco Multinu in
Google Scholar
PubMed
Search for other papers by Lavinia Benini in
Google Scholar
PubMed
Search for other papers by Michele Borghesani in
Google Scholar
PubMed
Search for other papers by Laura Algeri in
Google Scholar
PubMed
Search for other papers by Manila Rubino in
Google Scholar
PubMed
Search for other papers by Eleonora Pisa in
Google Scholar
PubMed
Search for other papers by Lorenzo Gervaso in
Google Scholar
PubMed
Search for other papers by Chiara Alessandra Cella in
Google Scholar
PubMed
Search for other papers by Silvestro Carinelli in
Google Scholar
PubMed
Search for other papers by Simone Bruni in
Google Scholar
PubMed
Search for other papers by Gabriella Schivardi in
Google Scholar
PubMed
Department of Oncology and Hemato-Oncology (DIPO), University of Milan, Milan, Italy
Search for other papers by Giuseppe Curigliano in
Google Scholar
PubMed
Search for other papers by Vanna Zanagnolo in
Google Scholar
PubMed
Division of Gynecologic Surgery, European Institute of Oncology, IRCCS, Via Ripamonti, Milan, Italy
Search for other papers by Giovanni Aletti in
Google Scholar
PubMed
Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy
Search for other papers by Nicoletta Colombo in
Google Scholar
PubMed
Search for other papers by Nicola Fazio in
Google Scholar
PubMed
Non-metastatic neuroendocrine carcinoma of the cervix (NECC) is a rare and aggressive disease. Lacking prospective studies, the optimal multimodal treatment approach has not yet been clearly defined. This study aims to assess the clinical outcomes of patients with non-metastatic NECC treated with surgery and (neo)adjuvant chemotherapy, according to pathologic prognostic factors and multimodal treatments received. We retrospectively examined data from patients with non-metastatic NECC candidate to receive surgery and (neo)adjuvant chemotherapy and discussed at the European Institute of Oncology’s Multidisciplinary Neuroendocrine Tumor Board, between January 2003 and December 2021. Primary endpoints were event-free survival and overall survival. A total of 27 consecutive patients were evaluated, 15 with early stage NECC and 12 with a locally advanced NECC. Eight patients received neoadjuvant and 19 adjuvant platinum-based chemotherapy; 14 received adjuvant pelvic radiotherapy, half with external-beam radiation therapy alone, and half combined with brachytherapy. No patients progressed or relapsed during (neo)adjuvant chemotherapy. The median event-free survival was 21.1 months and the median overall survival was 33.0 months. Pathological FIGO stage ≥ IIB, adjuvant external-beam radiation therapy with or without brachytherapy emerged as significant and independent prognostic factors for event-free survival. Brachytherapy was also prognostic for overall survival. Non-metastatic NECC requires a multimodal approach, mainly weighted on the FIGO stage. The addition of brachytherapy should be considered, especially in patients with locally advanced disease. Because of the scarcity of robust clinical data, treatment strategy should be discussed in multidisciplinary board, taking into account patient.
Search for other papers by Nicola Fazio in
Google Scholar
PubMed
Molecular Medicine Program, University of Pavia, Pavia, Italy
Search for other papers by Lorenzo Gervaso in
Google Scholar
PubMed
Search for other papers by Thorvardur R Halfdanarson in
Google Scholar
PubMed
Search for other papers by Mohamad Sonbol in
Google Scholar
PubMed
Search for other papers by Rachel A Eiring in
Google Scholar
PubMed
Search for other papers by Sara Pusceddu in
Google Scholar
PubMed
Search for other papers by Natalie Prinzi in
Google Scholar
PubMed
Search for other papers by Benedetta Lombardi Stocchetti in
Google Scholar
PubMed
Search for other papers by Simona Grozinsky-Glasberg in
Google Scholar
PubMed
Search for other papers by David J Gross in
Google Scholar
PubMed
Search for other papers by Thomas Walter in
Google Scholar
PubMed
Search for other papers by Patrick Robelin in
Google Scholar
PubMed
Search for other papers by Catherine Lombard-Bohas in
Google Scholar
PubMed
Search for other papers by Samuele Frassoni in
Google Scholar
PubMed
Search for other papers by Vincenzo Bagnardi in
Google Scholar
PubMed
Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
Search for other papers by Lorenzo Antonuzzo in
Google Scholar
PubMed
Search for other papers by Clotilde Sparano in
Google Scholar
PubMed
Search for other papers by Sara Massironi in
Google Scholar
PubMed
Search for other papers by Fabio Gelsomino in
Google Scholar
PubMed
Search for other papers by Alberto Bongiovanni in
Google Scholar
PubMed
Search for other papers by Nicoletta Ranallo in
Google Scholar
PubMed
Search for other papers by Salvatore Tafuto in
Google Scholar
PubMed
Search for other papers by Maura Rossi in
Google Scholar
PubMed
Search for other papers by Mauro Cives in
Google Scholar
PubMed
Search for other papers by Ibrahim Rasul Kakil in
Google Scholar
PubMed
Search for other papers by Hytam Hamid in
Google Scholar
PubMed
Search for other papers by Alessandra Chirco in
Google Scholar
PubMed
Search for other papers by Michela Squadroni in
Google Scholar
PubMed
Search for other papers by Anna La Salvia in
Google Scholar
PubMed
Search for other papers by Jorge Hernando in
Google Scholar
PubMed
Search for other papers by Johannes Hofland in
Google Scholar
PubMed
Search for other papers by Anna Koumarianou in
Google Scholar
PubMed
Search for other papers by Sabrina Boselli in
Google Scholar
PubMed
Search for other papers by Darina Tamayo in
Google Scholar
PubMed
Search for other papers by Cristina Mazzon in
Google Scholar
PubMed
Search for other papers by Manila Rubino in
Google Scholar
PubMed
Search for other papers by Francesca Spada in
Google Scholar
PubMed
We conducted a retrospective/prospective worldwide study on patients with neuroendocrine neoplasms (NENs) and a molecularly proven SARS-CoV-2 positivity. Preliminary results regarding 85 patients of the INTENSIVE study have been published in 2021. Now we are reporting the 2-year analysis.Here, we are reporting data from consecutive patients enrolled between 1 June 2020, and 31 May 2022. Among the 118 contacted centers, 25 were active to enroll and 19 actively recruiting at the time of data cut-off for a total of 280 patients enrolled. SARS-CoV-2 positivity occurred in 47.5% of patients in 2020, 35.1% in 2021, and 17.4% in 2022. The median age for COVID-19 diagnosis was 60 years. Well-differentiated tumors, non-functioning, metastatic stage, and gastroenteropancreatic (GEP) primary sites represented most of the NENs. COVID-19-related pneumonia occurred in 22.8% of the total, with 61.3% of them requiring hospitalization; 11 patients (3.9%) needed sub-intensive or intensive care unit therapies and 14 patients died (5%), in 11 cases (3.9%) directly related to COVID-19. Diabetes mellitus and age at COVID-19 diagnosis > 70 years were significantly associated with COVID-19 mortality, whereas thoracic primary site with COVID-19 morbidity. A significant decrease in both hospitalization and pneumonia occurred in 2022 vs 2020. In our largest series of NEN patients with COVID-19, the NEN population is similar to the general population of patients with NEN regardless of COVID-19. However, older age, non-GEP primary sites and diabetes mellitus should be carefully considered for increased COVID-19 morbidity and mortality. Relevant information could be derived by integrating our results with NENs patients included in other cancer patients with COVID-19 registries.
